Tumor-associated neutrophils: new targets for cancer therapy.

By A. Gregory, A. M. Houghton. Cancer Research, 2011

675 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Immunology

View Paper: https://www.semanticscholar.org/paper/2d866f352207dd148dd6dd4197bafd091ab8f73f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Jong-Sup Bae
2. A. Mantovani
3. A. Mócsai
4. Jaehong Kim
5. C. Garlanda

In Immunology

1. C. Garlanda
2. A. Mantovani
3. S. Jaillon
4. M. Galdiero
5. Jong-Sup Bae
6. Jaehong Kim
7. A. Mócsai
8. C. Lowell

Citations in the corpus

• Tumor associated macrophages and neutrophils in cancer. (2013, background): “…their effector molecules has been proposed as anti-tumoral therapeutic obiolo s e l s 2 i P c r p a P g F c p b w 2 l c t 2 c o e b t ( h 2 i p a h s R t g c T c f T m h e C i m m p t M 2 m M.R. Galdiero et al. / Immun trategies (Citro et al. 2012; Gregory and Houghton 2011; Jamieson t al.”
• Diverse novel functions of neutrophils in immunity, inflammation, and beyond (2013, background): “The readers are referred to recent reviews for further information on this very interesting but diverse field of study (Gregory and Houghton, 2011; Fridlender and Albelda, 2012).”
• Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases (2017, neutral): “Indeed, CXCR1/2 ligands played a significant role in neutrophil tumor infiltration that facilitated cancer cell proliferation, invasion, and chemoresistance via increased levels of angiogenic and growth factors produced by these tumor-associated neutrophils [125, 364-366].”
• The Multifaceted Functions of Neutrophils (2013, background): “In fact, many of the properties ascribed to TANs, such as high arginase 1 production, are also ascribed to MDSCs; hence, these may just be differentially activated variants of the same cell type (247).”
• Tumor-associated neutrophils: friend or foe? (2012, neutral): “tumor cell lines, or following specific therapies [7].”
• Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment (2016, methodology): “For this purpose, the deployment of anti-CXCR2 antibodies to deplete TANs or the targeting of specific neutrophil-derived or recruiting chemokines, such as CXCL-5, Gro-α, or IL-8, was performed and reported to be successful [59].”